S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:PSNL - Personalis Stock Price, Forecast & News

$11.76
-0.65 (-5.24 %)
(As of 01/20/2020 10:45 AM ET)
Today's Range
$11.64
Now: $11.76
$12.68
50-Day Range
$8.73
MA: $10.05
$12.40
52-Week Range
$8.48
Now: $11.76
$31.88
Volume724,496 shs
Average Volume573,660 shs
Market Capitalization$367.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees147
Market Cap$367.26 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Many traders become obsessed with the big win. But successful trading isn't about hitting home runs, it's about raising your batting average.

Rob Booker has the blueprint for steady, reliable account growth, like $100 a day, every day, even with tiny accounts. Do you want to leverage incredible risk/reward ratios in your favor?

Personalis (NASDAQ:PSNL) Frequently Asked Questions

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) issued its earnings results on Wednesday, November, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The company earned $17.20 million during the quarter, compared to analyst estimates of $15.77 million. The firm's revenue was up 47.0% on a year-over-year basis. View Personalis' Earnings History.

When is Personalis' next earnings date?

Personalis is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Personalis.

What guidance has Personalis issued on next quarter's earnings?

Personalis updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$64.5-65 million, compared to the consensus revenue estimate of $$61.68 million.

What price target have analysts set for PSNL?

5 equities research analysts have issued 1-year price targets for Personalis' shares. Their forecasts range from $22.00 to $29.00. On average, they anticipate Personalis' stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 123.2% from the stock's current price. View Analyst Price Targets for Personalis.

What is the consensus analysts' recommendation for Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.

Has Personalis been receiving favorable news coverage?

Media stories about PSNL stock have trended positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Personalis earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Personalis.

Are investors shorting Personalis?

Personalis saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 23.3% from the December 15th total of 1,030,000 shares. Based on an average trading volume of 403,200 shares, the days-to-cover ratio is presently 3.1 days. Currently, 7.8% of the shares of the stock are short sold. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Editas Medicine (EDIT), CVS Health (CVS), Verizon Communications (VZ), Home Depot (HD), Honeywell International (HON), Raytheon (RTN), Thermo Fisher Scientific (TMO) and QUALCOMM (QCOM).

Who are Personalis' key executives?

Personalis' management team includes the folowing people:
  • Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
  • Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

When did Personalis' lock-up period expire?

Personalis' lock-up period expired on Tuesday, December 17th. Personalis had issued 7,921,500 shares in its initial public offering on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are Personalis' major shareholders?

Personalis' stock is owned by many different of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.17%). View Institutional Ownership Trends for Personalis.

Which institutional investors are buying Personalis stock?

PSNL stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Personalis.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $11.76.

How big of a company is Personalis?

Personalis has a market capitalization of $367.26 million. Personalis employs 147 workers across the globe.View Additional Information About Personalis.

What is Personalis' official website?

The official website for Personalis is http://www.personalis.com/.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


MarketBeat Community Rating for Personalis (NASDAQ PSNL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel